Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2007-03-13
2007-03-13
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S216100, C424S217100, C424S093200, C435S235100, C435S236000, C435S320100, C536S023720
Reexamination Certificate
active
09647911
ABSTRACT:
The present invention provides modified viral genomes for use as vaccines or vectors, which are improved in their ability to retain attenuating mutations. The genomes are from viruses that replicate by way of an RNA-dependent RNA or DNA polymerase. The genomes are modified in the pol gene to encode polymerases that catalyze slower replication, have increased transcriptional fidelity, or are otherwise altered such that the reversion rate of the modified virus to a non-attenuated form is decreased as compared to an equivalent, unmodified virus. In particular, modified coxsackievirus genomes are disclosed.
REFERENCES:
patent: 5869036 (1999-02-01), Belshe et al.
Walker et al., Journal of Virology, Dec. 1995, p. 8173-8177.
Baker et al., Journal of General Virology (1995), 76, 2081-2084.
Jablonski et al (Journal of Virology 65: 4564-4572, 1991).
Bell et al, Journal of Virology 73:9413-9421, 1999.
Parsley et al, Journal of Biological Chemistry 274:12867-12876, 1999.
Cornell et al, Journal of Virology 78:4397-4407, 2004.
Cornell et al, Journal of Virology 78:13007-13018, 2004.
Cornell et al, Virology 298:200-213, 2002.
Gohara et al, Journal of Biological Chemistry 275:25523-25532, 2000.
Bowles, N.E. et al., Detection of Coxsackie-B-Virus-Specific RNA Sequences In Myocardial Biopsy Samples From Patients With Myocarditis And Dilated Cardiomyopathy. The Lancet 1120-1122 (1986).
Chapman, N.M. et al., Genetics of Coxsackievirus Virulence. Current Topics in Microbiology and Immunology 223:227-258 (1997).
Domingo, E. and Holland, J.J., RNA Virus Mutations and Fitness for Survival. Annu. Rev. Microbiol. 51:151-178 (1997).
Evans, D.M.A. et al., Increased Neurovirulence Associated with a Single Nucleotide Change in a Noncoding Region of the Sabin Type 3 Poliovaccine Genome. Nature 314:548-550 (1985).
Hansen, J.L. et al., Structure of the RNA-Dependent RNA Polymerase of Poliovirus. Structure 5:1109-1122 (1997).
Jablonski, S.A. et al., Enzymatic Activity of Poliovirus RNA Polymerase Mutants with Single Amino Acid Changes in the Conserved YGDD Amino Acid Motif. Journal of Virology 65:4565-4572 (1991).
Jacobo-Molina, A., et al., Crystal Structure of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Complexed with Double-Stranded DNA at 3.0 Å Resolution Shows Bent DNA, Proc. Natl. Acad. Sci. USA 90:6320-6324 (1993).
Lee, C. et al., Genomic Regions of Coxsackievirus B3 Associated with Cardiovirulence. J. Med. Virol. 52:341-347 (1997).
Macadam, A.J. et al., An Assembly Defect as a Result of an Attenuating Mutation in the Capsid Proteins of the Poliovirus Tyupe 3 Vaccine Strain. Journal of Virology 65:5225-5231 (1991).
Macadam, A.J. et al., Reversion of the Attenuated and Temperature-Sensitive Phenotypes of the Sabin Type 3 Strain of Poliovirus in Vaccinees. Virology 172:408-414 (1989).
Minor, P.D. et al., Genetic Basis of Attenuation of the Sabin Oral Poliovirus Vaccines, Biologicals 21:357-363 (1993).
O'Reilly, E.K. and Kao, C.C., Analysis of RNA-Dependent RNA Polymerase Structure and Function as Guided by Known Polymerase Structures and Computer Predictions of Secondary Structure. Virology 252:287-303 (1998).
Oude Essink, B.B., et al., Increased Polymerase Fidelity of the 3TC-Resistant Variants of HIV-1 Reverse Transcriptase. Nucleic Acids Research 25:3212-3217 (1997).
Ramsingh, A.I. and Collins, D.N., A Point Mutation in the VP4 Coding Sequence of Coxsackievirus B4 Influences Virulence. Journal of Virology 69:7278-7281 (1995).
Romero, J.R., et al., Genetic Divergence Among the Group B Coxsachieviruses. Current Topics in Microbiology and Immunology 2232:97-152 (1997).
Rubinek, T. et al., The Fidelity of 3′ Misinsertion and Mispair Extension during DNA Synthesis Exhibited by Two Drug-Resistant Mutants of the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 with Leu74→Val and Glu89→Gly. Eur. J. Biochem. 247:238-247 (1997).
Sousa, R. et al., Crystal Structure of Bacteriophage T7 RNA Polymerase at 3.3 Å Resolution. Nature 364:593-599 (1993).
Tracy, S. et al., Genetics of Coxsackievirus B Cardiovirulence and Inflammatory Heart Muscle Disease. Trends in Microbiology 4:175-179 (1996).
Wainberg, M.A., Increased Fidelity of Drug-Seelected M184V Mutated HIV-1 Reverse Transcriptase as the Basis for the Effectiveness of 3TC in HIV Clinical Trials. Leukemia Apr. 11 Supp. 3:85-88 (1997).
Zhang, H. et al., Coxsackievirus b3-Induced Myocarditis: Characterization of Stable Attenuated Variants that Protect Against Infection with the Cardiovirulent Wild-Type Strain. American Journal of Pathology 150:2197-2207 (1997).
Zhang, H.Y. et al., Attenuation of a Recativated Cardiovirulent Coxsackievirus B3: The 5′-Nontranslated Region Does Not Contain Major Attenuation Determinants. Journal of Medical Virology 41:129-137 (1993).
Chapman Nora M.
Tracy Steven M.
Mosher Mary E.
University of Nebraska Board of Regents
Woodcock & Washburn LLP
LandOfFree
Live attenuated viruses for use as vectors or vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live attenuated viruses for use as vectors or vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live attenuated viruses for use as vectors or vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732123